Setmelanotide
Also known as: Imcivree, RM-493
Key Facts: Setmelanotide
- Category
- Weight Loss
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Specific genetic obesities
- Administration
- Subcutaneous injection daily
- Typical Dose
- 2-3 mg daily
- Frequency
- Once daily
- Evidence Level
- FDA Approved
- Duration
- Long-term / chronic use
What to Expect
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Mechanism of Action
Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that's disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling.
Research Summary
Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach.
Dosing Information
Typical Dosingⓘ
Community experience
2-3 mg daily
1-3 mg daily
Once daily
FDA-approved for specific genetic obesities (POMC, PCSK1, LEPR deficiency). Prescription only.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
2-3 mg daily (adults)
Weight-based dosing (pediatric)
Duration
Long-term / chronic use
Administration
Subcutaneous injection daily
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Skin hyperpigmentation (67-83%)
- ●Injection site reactions
- ●Nausea
- ●Spontaneous erections in males
- ●Priapism risk
- ●Depression risk
- ●FDA approved (Imcivree)
References
Related Peptides
Peptides commonly compared with Setmelanotide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossDulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Weight LossExenatide
FDAThe first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Weight LossSemaglutide Oral
FDAThe oral formulation of semaglutide using SNAC absorption enhancer. First oral GLP-1 receptor agonist FDA approved.
Weight LossWant updates on Setmelanotide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.